<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02338323</url>
  </required_header>
  <id_info>
    <org_study_id>FB2015</org_study_id>
    <nct_id>NCT02338323</nct_id>
  </id_info>
  <brief_title>Compare the Renal Protective Effects of Febuxostat and Benzbromarone</brief_title>
  <official_title>Compare the Renal Protective Effects of Febuxostat and Benzbromarone in Chronic Kidney Disease Patients With GFR 20-50ml/Min</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai 10th People's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai 10th People's Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether febuxostat and benzbromarone could protect
      renal function, and which one could be better.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Chronic kidney disease patients with hyperuricemia and glomerular filtration rate (GFR) 20-50
      ml/min were treated by febuxostat or benzbromarone. Follow up the changes of serum uric acid,
      serum creatinine and GFR levels. Compare the effects on renal function of these two drugs.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2015</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Renal function</measure>
    <time_frame>up to 12th months</time_frame>
    <description>Blood test for serum uric acid and creatinine, according to equation to estimate glomerular filtration rate</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>urine protein</measure>
    <time_frame>3rd months, 6th months, 9th months, 12th months</time_frame>
    <description>urine test for microprotein markers and 24-hour urine protein quantitation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>adverse drug reaction</measure>
    <time_frame>1st month, 2nd months, 3rd months, 6th months, 9th months, 12th months</time_frame>
    <description>record all the adverse drug reactions</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Chronic Kidney Disease</condition>
  <condition>Hyperuricemia</condition>
  <condition>Abnormal Renal Function</condition>
  <arm_group>
    <arm_group_label>Febuxostat</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>take orally, 40mg per day, for 1 year</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Benzbromarone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>take orally, 50mg per day, for 1 year</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Febuxostat</intervention_name>
    <description>It acts as an inhibitor of xanthine oxidase, thus lowering urate concentrations in the body</description>
    <arm_group_label>Febuxostat</arm_group_label>
    <other_name>Uloric</other_name>
    <other_name>Adenuric</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Benzbromarone</intervention_name>
    <description>It is structurally related to the antiarrhythmic amiodarone, and it is a uricosuric agent and non-competitive inhibitor of xanthine oxidase</description>
    <arm_group_label>Benzbromarone</arm_group_label>
    <other_name>Desuric</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Chronic kidney disease patients with glomerular filtration rate (GFR,20-50ml/min) who match
        one of the following criteria:

          1. Gout

          2. Hyperuricemia patients without gout but have cardiovascular risk and serum uric acid &gt;
             480umol/L

          3. Hyperuricemia patients without gout but with serum uric acid &gt; 540umol/L

        Exclusion Criteria:

          1. GFR&lt;20ml/min or GFR &gt;50ml/min

          2. Liver dysfunction (Aspartate transaminase or/and alanine aminotransferase exceed 2
             times of normal range)

          3. Urinary tract obstruction

          4. unstable angina, heart failure (stage III-IV, NYHA), new stroke, need diuretics for
             long-term treatment

          5. Severe lung diseases or cancers

          6. Pregnant woman or woman who prepare to be pregnant，nursing mothers

          7. unable to sign informed consent form，or disagree with following-up
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ling Wang, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Nephrology &amp; Rheumatology, Shanghai Tenth People's Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ai Peng, MD, PhD</last_name>
    <email>pengai@tongji.edu.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Nephrology &amp; Rheumatology, Shanghai Tenth People's Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200072</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ai Peng, MD, PhD</last_name>
      <email>pengai@tongji.edu.cn</email>
    </contact>
    <contact_backup>
      <last_name>Ling Wang, MD, PhD</last_name>
      <email>nowax@126.com</email>
    </contact_backup>
    <investigator>
      <last_name>Ling Wang, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 10, 2015</study_first_submitted>
  <study_first_submitted_qc>January 13, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 14, 2015</study_first_posted>
  <last_update_submitted>May 5, 2016</last_update_submitted>
  <last_update_submitted_qc>May 5, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 6, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai 10th People's Hospital</investigator_affiliation>
    <investigator_full_name>Ai Peng</investigator_full_name>
    <investigator_title>Chief of department of Nephrology &amp; Rheumatology</investigator_title>
  </responsible_party>
  <keyword>Hyperuricemia</keyword>
  <keyword>Renal Function</keyword>
  <keyword>Chronic kidney disease</keyword>
  <keyword>Febuxostat</keyword>
  <keyword>Benzbromarone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
    <mesh_term>Hyperuricemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Febuxostat</mesh_term>
    <mesh_term>Benzbromarone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

